Core Viewpoint - The company has entered into an exclusive licensing agreement with Qilu Pharmaceutical for the research, development, and commercialization of LAE002 (afuresertib) in specified regions of China, which is expected to enhance its financial strength and accelerate the drug's market approval process [1][2]. Group 1 - The licensing agreement grants Qilu Pharmaceutical exclusive rights to LAE002 (afuresertib) in China, including mainland China, Hong Kong, Macau, and Taiwan [1]. - The company will receive a total of up to RMB 5.3 billion in non-refundable upfront and milestone payments until the first indication receives new drug application approval in China [1]. - The total potential upfront and milestone payments from the agreement could reach RMB 20.45 billion, along with a tiered sales revenue share ranging from over ten percent to over twenty percent [1]. Group 2 - The board believes that the licensing agreement aligns with the best interests of the company and its shareholders, allowing for accelerated regulatory approval and commercialization of LAE002 (afuresertib) [2]. - The upfront and milestone payments are expected to strengthen the company's financial position, supporting future development initiatives [2]. - The company is actively engaging with multiple potential partners to establish strategic collaborations aimed at expediting the clinical development and commercialization of its drug candidates [2].
来凯医药-B(02105.HK)与齐鲁制药签独家许可，获高额首付款及里程碑款